Fig. 1
From: CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
A Tissue microarrays of GC tumour tissues, paracancerous tissues and metastatic lymph nodes stained for the CLDN18.2 protein (4× and 20× magnifications). B Differential expression of CLDN18.2 in tumour and paracancerous tissues of GC. C Differential expression of CLDN18.2 in tumour tissues and metastatic lymph nodes of GC. D, E Kaplan‒Meier OS curves of GC patients with different CLDN18.2 levels in tumour tissues (log-rank test). * Statistically significant (P < 0.05). F-H Differences in CLDN18.2 expression levels by Borrmann type, Lauren type, and grade of differentiation